SCHEMBL2384313

SCHEMBL2384313

NNc1c(C(N)=O)c2c(N)ncnc2n1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 1/20 1.00
HSPA8 P11142 5/20 0.83
CDK2 P24941 3/20 0.74
CDK1 P06493 2/20 0.74
CCNA2 P20248 2/20 0.74
CCNA1 P78396 2/20 0.74
CCNB1 P14635 1/20 0.74
CDK5 Q00535 2/20 0.57
CDK5R1 Q15078 1/20 0.57
HSPA5 P11021 2/20 0.53
ADK P55263 4/20 0.52
DOT1L Q8TEK3 3/20 0.52
DCLK1 O15075 1/20 0.52
DAPK3 O43293 1/20 0.52
DYRK3 O43781 1/20 0.52
ROS1 P08922 1/20 0.52
RPS6KB1 P23443 1/20 0.52
FLT3 P36888 1/20 0.52
CSNK1A1 P48729 1/20 0.52
CSNK1D P48730 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2384317 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL12284814 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL29780006 1.00 HIF1A (1.00) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141370 0.90 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111064 0.90 HIF1A (0.81) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141362 0.88 HIF1A (0.79) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL22111053 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL30131081 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141988 0.87 HIF1A (0.77) HIF1AHSPA8CDK2CDK1CCNA2
SCHEMBL20141359 0.86 HIF1A (0.75) HIF1AHSPA8CDK2CDK1CCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2214670-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION Taiga Biotechnologies, Inc. (US) 2010-08-11 EP claimed
WO-2009059304-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION TAIGA BIOTECHNOLOGIES, INC. (US) 2009-05-07 WO claimed
US-20110218210-A1 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION Taiga Biotechnologies (US) 2011-09-08 US disclosed
EP-2214670-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION Taiga Biotechnologies, Inc. (US) 2010-08-11 EP disclosed
WO-2009059304-A2 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION TAIGA BIOTECHNOLOGIES, INC. (US) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218210-A1 COMPOUNDS FOR TREATING ABNORMAL CELLULAR PROLIFERATION MKI67, PCNA, CCNC HIF1A 1802/4885HSPA8 2025/4885CDK2 24/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.